9 December 2020

Deciphex Delivers Industry-first Patholytix Digital Pathology Peer Review for GLP Studies in Partnership with Charles River Laboratories

DUBLIN, Ireland and WILMINGTON, Mass., December 09, 2020 – Deciphex and Charles River Laboratories International, Inc. (NYSE: CRL) have jointly announced today that they are the first in the industry to offer clients Good Laboratory Practice (GLP) validated digital peer review, using Deciphex Patholytix Preclinical for toxicologic pathology. This progress has been driven by close collaboration between Deciphex, Charles River regulatory experts and partners in Pharma. Charles River will leverage Patholytix Preclinical from Deciphex, to pave the way for fully compliant GLP digital peer reviews to streamline and expedite the process of ensuring the quality and integrity of studies.

Peer review is an industry best practice to maintain the high-quality and standard of safety studies. Traditional methods can be cumbersome, requiring the manual packing and shipping of hundreds of glass slides or extensive travel of pathologists to other facilities for days of on-site reviews. Now for the first time, Deciphex enables GLP digital peer review allowing Charles River pathologists to scan and share slides with clients virtually for remote review and collaboration. The transition to digital helps accelerate the delivery of robust, decision-driving data and creates a faster, more efficient, more accurate, and standardized process for long-term operational and efficiency benefits. These enhancements ultimately reduce the drug delivery timeline and help save on costs related to study duration and travel. Additionally, in the era of COVID-19 when travel restrictions impact the ability to conduct these assessments in-person, the digital peer review will allow this step in the study process to continue uninhibited.

This offering builds on the previously announced collaboration between Deciphex and Charles River in March 2020, which centered on the co-development of a digital pathology workflow, along with the development of high performing validated AI algorithms for non-clinical pathology, to support accelerated pathology analytics. Through that partnership, Charles River also became the exclusive contract research organization distributing Patholytix Preclinical, Deciphex’s flagship product, to enhance capabilities in both digital primary and peer review.

“In the midst of COVID-19, the need for digital tools to streamline our current processes has never been greater. Partnering with Charles River to enable the digital transformation of pathology will support the industry-leading digital pathology work being done globally to thrive.”– Donal O'Shea, Founder and Chief Executive Officer at Deciphex

“As part of Charles River’s continuing commitment to enable our clients to reach their development goals, we are excited to deliver a truly innovative GLP validated Digital Pathology Peer Review solution. By partnering closely with Deciphex, we have a transformational product, Patholytix Preclinical, that will drive greater efficiency and flexibility for study delivery across the globe.” – Kevin McDorman, Corporate Vice President of Pathology

About Deciphex

Deciphex is an Irish-based software company focused on developing digital pathology-based solutions for clinical and research pathology. Our ambition is to deliver solutions that provide tangible productivity benefits to pathologists, eliminating low-level tasks so they can focus on the critical content. We believe that digital pathology combined with artificial intelligence will help make pathologists work more efficiently in the future, offering a solution to the pending challenges in supply/demand in pathology services. Deciphex plans to be at the forefront of this revolution with cleverly positioned solutions that deliver on the biggest problems facing pathology today.

About Charles River

Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them. To learn more about our unique portfolio and breadth of services, visit www.criver.com.

INVESTOR/MEDIA CONTACT:

Mairin Rafferty
Chief Operating Officer
+353 86 1737932
mairin.rafferty@deciphex.com

INVESTOR CONTACT:

Todd Spencer
Corporate Vice President, Investor Relations
781-222-6455t
odd.spencer@crl.com

MEDIA CONTACT:

Amy Cianciaruso
Corporate Vice President, Public Relations
781-222-6168
amy.cianciaruso@crl.com